advanc
cancer
therapi
focus
attent
qualiti
life
cancer
survivor
sinc
infertil
major
concern
follow
chemotherapi
import
character
drugspecif
damag
reproduct
system
help
find
appropri
protect
strategi
studi
investig
damag
neonat
mous
ovari
maintain
vitro
day
expos
h
day
clinic
relev
dose
docetaxel
doc
low
mm
mid
mm
high
mm
furthermor
studi
explor
put
protect
action
exert
triiodothyronin
end
cultur
morpholog
analys
follicl
count
show
doc
neg
impact
earli
grow
follicl
decreas
primari
follicl
number
sever
affect
health
transit
primari
stage
poor
follicl
health
mainli
due
effect
granulosa
cell
indic
effect
doc
oocyt
like
secondari
granulosa
cell
damag
doc
damag
grow
follicl
specif
direct
effect
primordi
follicl
reserv
immunostain
western
blot
show
doc
induc
activ
intrins
type
ii
apoptosi
ovarian
somat
cell
increas
level
cleav
caspas
cleav
caspas
bax
cleav
poli
adpribos
polymeras
also
induc
movement
cytochrom
c
mitochondria
cytosol
prevent
damag
induc
low
dose
doc
result
demonstr
doc
induc
gonadotox
effect
mous
ovari
induct
somat
cell
apoptosi
evid
direct
effect
oocyt
damag
effect
mitig
consequ
advanc
modern
cancer
care
increas
number
women
longterm
survivor
follow
treatment
nevertheless
mani
case
patient
undergo
intens
treatment
experi
sever
sideeffect
either
immedi
even
year
therapi
well
recogn
anticanc
drug
gonadotox
infertil
repres
major
concern
women
undergo
cancer
treatment
particularli
younger
patient
meirow
et
al
key
basi
advers
effect
ovari
limit
suppli
oocyt
contain
within
ovarian
follicl
form
birth
popul
primordi
follicl
repres
femal
ovarian
reserv
reproduct
lifespan
woman
ceas
number
primordi
follicl
becom
low
less
around
thousand
lead
menopaus
wallac
kelsey
insult
patholog
circumst
affect
ovari
precoci
deplet
reserv
lead
prematur
ovarian
insuffici
poi
loss
fertil
consequ
estrogen
defici
sever
ovarian
toxic
caus
taxan
class
chemotherapeut
agent
difficult
determin
part
usual
administ
associ
drug
adjuv
han
et
al
et
al
torino
et
al
docetaxel
doc
second
gener
taxan
repres
one
power
chemotherapeut
drug
local
metastat
breast
nonsmal
cell
lung
ovarian
cancer
display
high
level
radiosensit
activ
gligorov
lotz
doc
trigger
cell
program
cell
death
pathway
mainli
bind
bsubunit
tubulin
thu
stabil
microtubul
inhibit
depolymer
result
cell
cycl
arrest
follow
phosphoryl
apoptosi
subrata
et
al
taxan
also
directli
chang
mitochondri
membran
permeabl
ultim
activ
caspas
fabbri
et
al
doc
plasma
concentr
patient
highli
variabl
differ
regimen
mg
administ
weekli
mg
administ
everi
week
use
clinic
pharmacokinet
studi
report
plasma
concentr
mm
maximum
concentr
c
max
rang
mm
within
h
posttreat
baker
et
al
slaviero
et
al
brunsvig
et
al
evid
clinic
studi
doc
increas
reproduct
impair
administ
combin
drug
martin
et
al
han
et
al
evid
anim
model
loss
primordi
follicl
treatment
relat
drug
paclitaxel
gucer
et
al
howev
effect
doc
particularli
controversi
work
show
patient
treat
taxan
restor
normal
menstrual
cyclic
frequent
treat
drug
minisini
et
al
zhou
et
al
ovarian
damag
difficult
assess
directli
studi
use
chemotherapyinduc
amenorrhoea
surrog
poi
method
allow
detect
incomplet
ovarian
damag
use
detail
assess
ovarian
function
previous
report
evid
taxaneinduc
toxic
women
treat
earli
breast
cancer
anderson
et
al
like
anticanc
drug
affect
ovarian
tissu
differ
accord
mechan
action
morgan
et
al
drugspecif
damag
therefor
need
character
defin
toxic
aim
find
protect
approach
one
possibl
protect
strategi
could
target
ovari
compound
antagon
chemotherapi
toxic
far
approach
explor
laboratori
studi
studi
investig
differ
molecular
approach
retrovirusmedi
multidrug
resist
gene
cabl
inhibitor
imatinib
morita
et
al
gonfloni
et
al
salih
morgan
et
al
one
exampl
kind
protect
approach
thyroid
hormon
hypothes
minim
impact
taxan
ovarian
function
due
role
cell
prolifer
apoptosi
ovarian
somat
cell
verga
falzacappa
et
al
date
one
report
shown
triiodothyronin
abl
counteract
apoptosi
rat
ovarian
gc
expos
taxan
paclitaxel
verga
falzacappa
et
al
cultur
system
neonat
mous
ovari
use
investig
docinduc
damag
rest
pool
primordi
follicl
earli
stage
follicular
develop
vitro
system
demonstr
reliabl
physiolog
model
studi
effect
compound
folliculogenesi
highli
control
environ
morgan
et
al
addit
order
explor
potenti
protect
strategi
role
supplement
investig
abil
prevent
docinduc
damag
intact
ovari
experi
approv
univers
edinburgh
local
ethic
review
committe
carri
accord
uk
home
offic
regul
mice
hous
h
h
dark
cycl
food
beverag
provid
ad
libitum
newborn
mous
ovari
cultur
perform
accord
morgan
et
al
brief
day
birth
femal
mice
sacrif
decapit
ovari
dissect
place
prewarm
leibovitz
medium
invitrogen
uk
supplement
mg
ml
bovin
serum
albumin
bsa
sigmaaldrich
ltd
uk
kept
whole
ovari
transfer
plate
grenier
bioon
stonehous
uk
contain
aminimum
essenti
medium
invitrogen
uk
supplement
ith
mg
ml
bsa
place
float
polycarbon
membran
whatman
nucleopor
polycarbon
membran
camlab
ltd
cambridg
uk
incub
co
atmospher
day
second
day
cultur
day
medium
supplement
ethanolvehicl
control
one
three
docetaxel
concentr
sigmaaldrich
ltd
uk
mm
lowdoc
mm
middoc
mm
highdoc
dose
doc
chosen
cover
rang
concentr
found
plasma
patient
undergo
cancer
treatment
baker
et
al
brunsvig
et
al
day
ovari
transfer
fresh
control
medium
half
medium
replac
day
cultur
continu
end
day
previou
work
use
experiment
paradigm
shown
time
frame
support
health
control
cultur
allow
growth
initi
major
follicl
morgan
et
al
intracellular
locat
cytochrom
c
examin
control
highdoc
treat
ovari
run
cytochrom
c
experi
four
ovari
dissect
mice
two
place
control
two
highdoc
condit
day
cultur
pair
ovari
process
western
blot
detail
experi
ovari
cultur
expos
day
ethanolvehicl
control
mm
doc
lowdoc
combin
mm
doc
suppli
sigmaaldrich
ltd
uk
lower
doc
dose
chosen
result
robust
increas
percentag
unhealthi
follicl
less
extens
damag
two
higher
dose
concentr
chosen
basi
previou
paper
show
concentr
abl
overcom
paclitaxelinduc
damag
gc
verga
falzacappa
et
al
verga
falzacappa
person
commun
ovari
group
also
expos
day
doc
day
cultur
finish
end
day
experi
ovari
process
end
cultur
period
histolog
western
blot
immunohistochemistri
ihc
detail
day
cultur
ovari
fix
bouin
fluid
embed
paraffin
wax
serial
section
mm
thick
collect
everi
sixth
section
stain
haematoxylin
eosin
photomicrograph
dmlb
leica
microscop
leica
microsystem
ltd
uk
follicl
count
perform
assessor
blind
treatment
use
imagej
softwar
total
number
follicl
per
ovari
estim
count
follicl
visibl
germin
vesicl
section
count
correct
use
abercrombi
formula
abercrombi
follicl
classifi
accord
morgan
et
al
follicl
consid
primordi
flatten
pregranulosa
cell
gc
present
transit
cuboid
gc
mix
flat
pregc
primari
stage
uniform
layer
cuboid
gc
present
follicl
health
assess
use
standard
morpholog
criteria
follicl
judg
unhealthi
oocyt
eosinophil
shrunken
nonhomogen
cytoplasm
condens
nuclear
chromatin
ii
gc
condens
chromatin
irregular
shape
iii
unhealthi
oocyt
gc
end
cultur
ovari
fix
neutral
buffer
formalin
sigmaaldrich
ltd
uk
overnight
wax
embed
serial
section
mm
ihc
cleav
caspas
mous
vasa
homologu
ovarian
toxic
docetaxel
neonat
mice
mvh
use
fluoresc
secondari
antibodi
ihc
cleav
caspas
use
avidinbiotin
visual
system
everi
section
dewax
rehydr
grade
seri
ethanol
water
slide
microwav
mm
sodium
citrat
fisher
chemic
loughborough
uk
block
normal
goat
serum
phosphatebuff
salin
pb
fisher
scientif
uk
ltd
uk
triton
pbst
bsa
slide
incub
overnight
rabbit
cell
signal
technolog
usa
mous
antimvh
abcam
uk
antibodi
wash
pbst
slide
incub
h
room
temperatur
secondari
antibodi
alexa
fluor
goat
antimous
igg
invitrogen
uk
goat
antirabbit
biotinyl
dakocytom
denmark
follow
min
room
temperatur
alexa
fluor
streptavidin
conjug
invitrogen
uk
wash
pbst
slide
counterstain
dapi
invitrogen
uk
mount
vectashield
mount
medium
vector
laboratori
usa
fluoresc
imag
taken
leica
microscop
camera
imag
analysi
perform
imagej
softwar
assessor
blind
treatment
follicl
count
mvhposit
oocyt
dapiposit
nucleu
visibl
section
instanc
apoptot
gc
andor
oocyt
record
degre
apoptot
cell
present
ovari
also
assess
measur
area
stain
cell
section
rel
area
dapi
section
one
two
middl
section
per
ovari
dewax
rehydr
grade
seri
ethanol
water
endogen
peroxidas
block
h
methanol
fisher
chemic
loughborough
uk
pb
microwav
mm
sodium
citrat
fisher
chemic
loughborough
uk
block
normal
goat
serum
pbst
bsa
slide
incub
overnight
rabbit
monoclon
antibodi
cell
signal
technolog
usa
wash
pbst
slide
incub
h
room
temperatur
biotinyl
secondari
goat
antirabbit
dakocytom
denmark
rewash
pbst
incub
avidin
biotinyl
horseradish
peroxidas
vectastain
elit
abc
kit
vector
laboratori
usa
min
visual
stain
diaminobenzidin
dab
vector
laboratori
usa
counterstain
haematoxylin
photomicrograph
dmlb
leica
microscop
leica
microsystem
ltd
uk
imag
analysi
perform
imagej
softwar
assessor
blind
treatment
degre
apoptot
cell
present
ovari
assess
measur
area
dabposit
stain
cell
section
rel
section
area
day
cultur
ovari
wash
icecold
pb
snap
frozen
dryic
twenti
microlitr
lysi
buffer
contain
mm
hepe
mm
nacl
triton
phosphatas
inhibitor
cocktail
sigmaaldrich
ltd
uk
complet
proteas
inhibitor
cocktail
roch
diagnost
ltd
uk
ad
two
ovari
homogen
centrifug
ovari
n
freez
underw
process
separ
mitochondria
cytosol
compon
mitochondria
isol
kit
cultur
cell
thermo
scientif
rockford
usa
modif
manufactur
instruct
case
mg
protein
load
onto
nupag
w
novex
w
bistri
precast
polyacrylamid
gel
invitrogen
uk
follow
electrophoresi
protein
transfer
onto
nitrocellulos
membran
membran
probe
overnight
antiparp
poli
adpribos
polymeras
rabbit
polyclon
antibodi
new
england
biolab
hertfordshir
uk
rabbit
monoclon
antibodi
x
protein
bax
abcam
cambridg
uk
rabbit
monoclon
antibodi
anticytochrom
c
abcam
cambridg
uk
rabbit
polyclon
antibodi
bactin
intern
standard
abcam
wash
fisher
chemic
loughborough
uk
pb
blot
incub
alexa
fluor
goat
antirabbit
invitrogen
uk
h
room
temperatur
fluoresc
detect
licor
scanner
odyssey
softwar
licor
bioscienc
usa
data
analys
use
graphpad
prism
softwar
normal
distribut
assess
use
nonparametr
test
distribut
kolmogorovsmirnov
test
determin
statist
signific
control
group
one
treatment
group
oneway
anova
follow
bonferroni
post
hoc
test
appli
normal
distribut
data
kruskal
walli
follow
dunn
post
hoc
test
appli
data
normal
distribut
control
compar
singl
treatment
pair
ttest
use
result
present
mean
sem
statist
signific
set
valu
p
docetaxel
affect
number
follicl
reach
primari
stage
newborn
mous
ovari
randomli
alloc
one
follow
experiment
group
control
n
lowdoc
n
middoc
n
highdoc
n
exposur
ovari
doc
led
specif
reduct
number
primari
follicl
fig
without
chang
overal
follicl
number
number
primari
follicl
significantli
reduc
ovari
expos
doc
dosedepend
fashion
fig
iv
total
follicl
number
per
ovari
vari
lowdoc
middoc
mark
decreas
observ
highdoc
compar
number
follicl
control
group
statist
signific
p
fig
similarli
number
primordi
transit
follicl
decreas
significantli
expos
doc
fig
ii
iii
follicl
health
affect
markedli
follicl
number
fig
fact
despit
rel
good
preserv
total
ovarian
follicl
popul
dramat
decreas
follicl
qualiti
observ
signific
increas
percentag
unhealthi
follicl
even
exposur
lowest
concentr
doc
fig
unhealthi
follicl
categor
within
development
stage
primordi
follicl
show
sign
damag
fig
contrast
grow
transit
primari
follicl
greatli
affect
doc
treatment
signific
increas
percentag
unhealthi
follicl
observ
fig
iv
although
lower
percentag
unhealthi
primari
follicl
highdoc
lowand
middoc
group
may
reflect
mark
deplet
follicl
stage
primari
follicl
left
ovari
fig
biv
ovarian
toxic
docetaxel
neonat
mice
docetaxel
primarili
affect
gc
earli
grow
follicl
order
analys
follicl
cell
type
princip
target
doc
damag
percentag
follicl
unhealthi
oocyt
gc
oocyt
gc
oo
gc
determin
fig
total
follicl
popul
consid
signific
increas
percentag
follicl
unhealthi
oocyt
rel
control
highdoc
group
fig
contrast
gc
markedli
affect
doc
exposur
even
lowest
drug
concentr
percentag
unhealthi
follicl
unhealthi
gc
rel
total
number
follicl
significantli
increas
dose
test
compar
follicl
classifi
unhealthi
due
poor
gc
control
group
fig
percentag
follicl
categor
unhealthi
due
unhealthi
oocyt
gc
oo
gc
also
significantli
greater
midand
highdoc
group
compar
control
fig
stage
follicl
develop
analys
separ
primordi
follicl
show
sign
damag
respons
drug
treatment
seen
control
primordi
follicl
fig
b
ii
biii
contrast
grow
transit
primari
follicl
case
significantli
affect
doc
treatment
exhibit
poor
gc
oogc
health
even
doserespons
manner
fig
biii
overal
result
indic
primari
cell
type
affect
doc
exposur
gc
grow
follicl
signific
increas
degener
even
lowest
concentr
grow
follicl
ovari
expos
lowdoc
dose
show
sign
pyknosi
primarili
local
gc
fig
abil
doc
induc
activ
intracellular
apoptot
pathway
mous
ovari
test
analys
express
follow
program
cell
death
marker
n
control
lowand
middoc
n
highdoc
n
control
lowdoc
n
midand
highdoc
examin
use
ihc
addit
western
blot
use
assess
express
bax
n
group
releas
cytochrom
c
cytc
mitochondria
cytosol
n
control
highdoc
group
cleavag
parp
cparp
n
group
express
analys
manual
count
also
use
autom
system
firstli
manual
count
number
follicl
oocyt
andor
gc
record
express
rel
number
follicl
section
follicl
count
determin
number
mvhexpress
oocyt
fig
f
doc
treatment
significantli
increas
proport
apoptot
follicl
rel
control
fig
secondli
semiautom
system
area
somat
granulosa
stromal
cell
within
section
measur
analys
rel
total
section
area
manual
count
area
apoptosi
increas
doctreat
group
fig
degre
activ
program
cell
death
follicl
detect
express
thu
reflect
degre
damag
observ
morpholog
observ
doc
treatment
furthermor
level
express
within
follicl
doctreat
ovari
compar
level
somat
cell
case
increas
fold
versu
control
noteworthi
match
outcom
system
confirm
reliabl
semiautom
system
reason
latter
system
chosen
analys
express
fig
treat
group
show
increas
level
comparison
untreat
tissu
fig
increas
follow
doserespons
pattern
signific
midand
highdoc
dose
fig
order
explor
docinduc
apoptot
pathway
western
blot
analysi
bax
cytc
cparp
perform
fig
bax
express
significantli
increas
rel
bactin
control
highdoc
group
fig
exposur
highdoc
also
induc
releas
cytc
mitochondria
cytosol
lead
decreas
ratio
mitochondri
cytosol
cytc
fig
parp
cleavag
show
signific
increas
rel
express
bactin
highdoc
group
fig
order
test
whether
play
put
protect
role
doc
damag
medium
supplement
presenc
lowdoc
n
absenc
n
lowdoc
data
compar
control
group
n
lowdoc
alon
n
alon
affect
normal
ovarian
morpholog
percentag
unhealthi
follicl
similar
control
group
previou
experi
fig
lowdoc
significantli
increas
percentag
follicl
classifi
unhealthi
fig
similar
degre
damag
obtain
lowdoc
ad
togeth
fig
therefor
indic
abl
protect
ovarian
follicl
docinduc
damag
concentr
use
potenti
design
protect
agent
strategi
reduc
ovarian
toxic
chemotherapi
regimen
requir
detail
understand
affect
cell
pathway
involv
use
vitro
mous
model
shown
doc
directli
impair
earli
stage
ovarian
follicl
develop
directli
affect
rest
pool
primordi
follicl
furthermor
demonstr
gc
grow
follicl
first
cellular
target
docinduc
follicular
damag
indic
oocyt
damag
indirect
doc
induc
damag
somat
cell
follow
mitochondrialdepend
apoptot
pathway
protect
effect
found
result
show
doc
induc
loss
follicl
earli
stage
growth
even
concentr
doc
mm
lower
found
plasma
cancer
patient
slaviero
et
al
baker
et
al
brunsvig
et
al
effect
must
due
either
decreas
number
follicl
reach
primari
stage
increas
number
die
soon
reach
primari
follicl
stage
moreov
exposur
low
concentr
doc
sever
impair
follicl
health
abnorm
morpholog
seen
transit
follicl
primari
follicl
scenario
becam
even
sever
drug
concentr
higher
rang
plasma
level
found
doctreat
patient
sever
group
use
vivo
vitro
rodent
model
test
effect
ovotox
compound
use
human
medicin
exampl
petrillo
et
al
maiani
et
al
cultur
system
use
present
studi
previous
use
laboratori
test
damag
caus
ovarian
follicl
popul
chemotherapeut
agent
includ
examin
chemotherapi
drug
cisplatin
consid
moder
clinic
ovotox
morgan
et
al
vitro
exposur
ovari
clinic
relev
dose
cisplatin
induc
similar
degre
damag
observ
present
studi
ovari
expos
clinic
relev
dose
doc
bear
mind
need
caution
extrapol
result
vitro
anim
model
consider
effect
doc
human
patient
togeth
indic
chemotherapeut
dose
doc
may
well
induc
moder
level
ovarian
toxic
certainli
examin
effect
doc
fertil
younger
femal
patient
warrant
limit
inform
impact
doc
patient
fertil
avail
larg
refer
length
temporari
time
perman
amenorrhoea
good
indic
partial
ovarian
damag
berlier
et
al
zhou
et
al
furthermor
within
studi
examin
degre
amenorrhoea
follow
doc
treatment
suggest
mark
effect
doc
martin
et
al
han
et
al
other
minisini
et
al
zhou
et
al
although
detail
analysi
indic
taxan
administr
combin
chemotherapi
agent
add
treatment
ovarian
toxic
anderson
et
al
best
knowledg
data
avail
anim
model
determin
detriment
effect
doc
fertil
vivo
studi
test
effect
first
gener
taxan
paclitaxel
primordi
follicl
adult
mice
contradictori
inject
mgkg
paclitaxel
consid
high
dose
singl
repeat
administr
decreas
primordi
follicl
count
week
drug
exposur
gucer
et
al
yucebilgin
et
al
contrast
anoth
vivo
studi
use
repeat
administr
paclitaxel
mgkg
adult
rat
found
reduct
follicl
count
preantral
develop
stage
antral
follicl
affect
tarumi
et
al
matur
oocyt
expos
paclitaxel
undergo
delay
nuclear
matur
defect
spindl
format
lead
aneuploidi
mailh
et
al
women
undergo
chemotherapi
usual
receiv
sever
treatment
period
month
human
ovarian
follicl
take
month
develop
dormant
state
fulli
grown
ovulatori
follicl
mcgee
hsueh
treatment
affect
rang
follicl
differ
development
stage
major
concern
ovarian
damag
markedli
affect
ovarian
reserv
rest
primordi
follicl
lead
poi
primordi
follicl
loss
could
result
direct
effect
damag
primordi
pool
could
indirect
effect
decreas
primordi
follicl
number
increas
rate
growth
initi
due
major
loss
grow
follicl
process
term
burnout
model
although
author
consid
matur
follicl
sensit
chemotherapi
small
follicl
nicosia
et
al
gucer
et
al
damag
specif
small
number
follicl
late
antral
stage
one
time
point
minor
impact
longterm
fertil
present
result
demonstr
immatur
earli
grow
follicl
sever
affect
doc
number
qualiti
even
low
doc
concentr
sinc
earli
grow
follicl
present
larg
number
mark
damag
follicl
pool
could
well
result
follicular
burnout
kalichphilosoph
et
al
morgan
et
al
burnout
model
also
accord
observ
other
use
high
dose
paclitaxel
mice
vivo
gucer
et
al
yucebilgin
et
al
present
studi
primordi
follicl
number
decreas
significantli
neg
trend
observ
highest
doc
concentr
may
reflect
particular
characterist
present
model
primordi
follicl
pool
mous
complet
form
birth
short
durat
experi
may
allow
full
elabor
secondari
effect
given
oocyt
somat
cell
follicl
mutual
interdepend
damag
latter
would
inevit
affect
health
oocyt
well
addit
loss
stromal
integr
could
aii
bii
cii
densitometr
analys
protein
express
rel
bactin
aii
cii
ratio
mitochondri
cytosol
express
bii
bax
cparp
express
increas
significantli
ovari
expos
highdoc
highdoc
treatment
also
induc
releas
cytochrom
c
mitochondria
cytosol
bax
total
six
ovari
use
treatment
group
three
independ
experi
kruskalw
follow
dunn
post
hoc
test
appli
cytc
total
ovari
use
treatment
group
five
independ
experi
pair
ttest
use
cparp
total
ovari
use
treatment
group
five
independ
experi
kruskalw
follow
dunn
post
hoc
test
appli
data
mean
sem
p
doc
versu
control
figur
thyroid
hormon
mitig
doc
damag
mous
ovari
percentag
unhealthi
follicl
ovari
cultur
signific
increas
percentag
follicl
unhealthi
follow
exposur
lowdoc
decreas
ovari
also
expos
total
ovari
use
per
group
four
independ
experi
control
lowdoc
kruskal
walli
follow
dunn
post
hoc
test
appli
data
mean
sem
asterisk
show
statist
signific
doc
treatment
rel
control
group
p
lead
subsequ
follicl
damag
present
studi
show
doc
sever
affect
earli
grow
follicl
initi
damag
gc
oocyt
damag
becom
appar
gc
compromis
data
also
suggest
doc
neg
impact
stromal
compon
ovari
seen
chemotherapi
drug
timelin
studi
damag
produc
doxorubicin
anthracyclin
agent
use
cancer
treatment
reveal
mous
stromal
tissu
first
target
probabl
due
contact
circulatori
system
roti
roti
et
al
furthermor
human
ovarian
cortex
cancer
patient
show
damag
blood
vessel
fibrosi
suggest
loss
stroma
integr
could
lead
follicl
damag
meirow
et
al
explan
docinduc
damag
probabl
lie
princip
mechan
action
group
chemotherapeut
drug
taxan
promot
microtubul
assembl
inhibit
polymer
lead
mitot
arrest
apoptosi
mitot
activ
cell
gc
stromal
cell
reason
like
vulner
doc
damag
oocyt
oocyt
death
would
follow
downstream
consequ
gc
damag
loss
oocytegc
connect
thomson
et
al
doc
mechan
action
may
also
explain
absenc
doserespons
pattern
damag
much
data
present
plateau
damag
perhap
alreadi
reach
lowest
concentr
abl
perturb
cell
cycl
divid
gc
within
activatedearli
grow
follicl
stroma
cell
time
doc
exposur
thu
ovari
expos
repeat
dose
rather
higher
dose
would
affect
increas
number
cell
subsequ
enter
phase
could
well
lead
wide
spread
damag
similarli
cytometr
studi
use
bladder
cancer
cell
line
american
type
cultur
collect
line
fail
find
doserespons
relationship
h
doc
treatment
h
treatment
induc
dosedepend
cytostati
fabbri
et
al
show
doc
activ
intrins
mitochondrialdepend
apoptot
pathway
somat
compart
ovari
induc
express
key
cell
death
marker
schemat
see
fig
procaspas
thought
first
intracellular
cystein
proteas
activ
upon
bind
cell
death
receptor
manab
et
al
gc
activ
intrins
type
ii
mitochondrialdepend
apoptot
cascad
subsequ
interact
proapoptot
famili
member
bax
sai
et
al
bax
proapoptot
protein
play
princip
role
mitochondria
involv
cell
death
undergo
conform
chang
integr
mitochondri
membran
henc
disrupt
membran
potenti
turn
induc
increas
permeabl
mitochondri
membran
consequ
releas
cytochrom
c
mitochondria
cytosol
liu
et
al
zhao
et
al
khan
et
al
cytochrom
c
activ
downstream
caspas
includ
effector
caspas
caspas
turn
lead
cleavag
nuclear
substrat
parp
inactiv
abil
support
dna
repair
longer
term
may
possibl
develop
protect
measur
gonadotox
effect
chemotherapeut
agent
propos
protect
exert
thyroid
hormon
investig
thyroid
hormon
involv
develop
function
reproduct
system
hypoand
hyperthyroid
associ
subfertil
stavreusev
propos
prevent
paclitaxelinduc
apoptosi
rat
gc
line
verga
falzacappa
et
al
present
studi
show
dose
unabl
prevent
ovarian
damag
induc
low
dose
doc
doc
paclitaxel
differ
doc
bind
tubulin
higher
affin
paclitaxel
capabl
direct
induct
apoptosi
via
phosphoryl
gligorov
lotz
nonetheless
discrep
data
result
verga
falzacappa
et
al
could
instead
due
markedli
differ
experiment
paradigm
use
suggest
organ
cultur
system
util
follicl
maintain
intact
abl
develop
intact
vivo
much
physiolog
gc
line
doc
dose
repres
lowest
dose
found
serum
sampl
treat
cancer
patient
concentr
use
verga
falzacappa
et
al
almost
time
higher
serum
concentr
healthi
peopl
time
patient
thyrotoxicosi
sterl
et
al
conclus
present
studi
mice
show
clear
evid
ovarian
toxic
doc
clinic
relev
concentr
model
use
allow
analysi
effect
later
stage
follicl
growth
demonstr
effect
stage
highli
relev
longterm
fertil
name
earli
grow
follicl
doc
demonstr
caus
loss
primari
follicl
evid
direct
effect
primordi
follicl
primordi
follicl
could
howev
site
secondari
effect
increas
activ
thu
prematur
deplet
